During the most recent 90-day period, previous to the date of this filing, there have been 40 insider transactions reported to the SEC for Regeneron Pharmaceuticals. These transactions came from the activities of 13 different insiders that resulted in a net disposition of 258,737 company shares. Relative to the preceding 90-day window of time, there were 50 transactions from 19 insiders that resulted in the net acquisition of 1,353,202 shares.
This is lower than the average level of insider transactions in the 324-company Bio Therapeutic Drugs peer group over the last 90-day period. Activity in the peer group averaged 45.7 transactions per company, with company insiders acquiring on average 19,365 shares.
SEC Story Link http://www.sec.gov/Archives/edgar/data/872589/000170813820000032/xslF345X03/edgardoc.xml
|Consensus for Zumiez Q2 Earnings Raised but Full Yea...|
|Williams Sonoma's Q2, 2021, 2022 Full Year Earnings ...|
|Analysts' Ratchet Up 2020, 2021 Consensus Estimates ...|
|Q1, 2021, 2022 Earnings Estimates for Advanced Drain...|
|Q2 Projection for Westlake Chemical Increased but 20...|